Panel features
CLIA-validated, ultra-sensitive blood test for the detection of BCOR, BRAF, CEBPA, FLT3, GATA2, IDH1, IDH2, JAK2, KIT, KRAS, NPM1, NRAS, PRPF8, PTPN11, SETBP1, SF3B1, SRSF2, TP53, U2AF1, and ZRSR2. This panel detects as few as 7 mutant molecules in a background of 20,000 wild-type molecules (0.035% mutant allele frequency).
GENE | GENE REGIONS COVERED (AMINO ACIDS) | CLINICAL RELEVANCE |
---|---|---|
FLT3 | 438-461, 479-493, 582-605, 663-684, 829-845 | Established therapeutic indications, monitored for reduction/ clearance |
IDH1 | 127-135, 256-281 | |
IDH2 | 135-154, 171-178, 310-322 | |
NPM1 | 260-275, 283-288 | Established clinical validity for MRD |
BCOR | 333-358, 395-421, 577-605, 822-846, 1477-1489, 1513-1527, 1533-1555, 1636-1658 | Prognostic markers typically detected with low sensitivity, qualitatively, at a single timepoint. Ultra-high sensitivity quantitative detection across multiple timepoints may reveal validity for MRD. |
BRAF | 582-604 | |
CEBPA | 61-86, 296-321 | |
GATA2 | 301-329, 350-379, 382-400 | |
JAK2 | 607-620 | |
KIT | 188-201, 412-425, 550-564, 808-828 | |
KRAS | 12-36, 57-76, 110-117, 141-148 | |
NRAS | 1-17, 55-70 | |
PRPF8 | 674-692, 1574-1595, 1597-1611, 1743-1769 | |
PTPN1 1 | 58-72 | |
SETBP 1 | 856-877 | |
SF3B1 | 622-644, 661-677, 699-722, 833-841 | |
SRSF2 | 75-95 | |
TP53 | 10-24, 26-32, 49-77, 99-125, 126-141, 151-179, 192-219, 225-248, 262-285, 297-306, 308-331, 332-360, 368-383 | |
U2AF1 | 30-40, 146-159 | |
ZRSR2 | 47-63, 69-71, 118-133, 171-185, 287-311 |